Log In

Baudax Bio Inc. (BXRX)

Nasdaq Delist Determination Letter Received; Plan To Be Presented To Regain Compliance

‌
Gregory AurandMedia Inquiries
Senior Healthcare Services & Medical Devices Analyst
May 22, 2023
Report ID: 25875
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.
Get Report

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

‌
Baudax Bio Inc.
Baudax Bio Inc.
Healthcare
Biotechnology
Ticker
BXRX
Current Price
$0.3 -3.32%
Market Cap
$2.1M
Price Target
Refer to Report
Volume
184.6K
52wk Range
$0.3 - $12.24
Fundamental Analysis:
Log in to view
Rating: Log in to view
Advanced Market Data
Related Research Reports
8/23/2023
‌
A New Phase Begins For Baudax Bio With Reported 2Q 2023
A New Phase Begins For Baudax Bio With Reported 2Q 2023 (BXRX)
5 min read
7/26/2023
‌
Nasdaq Hearings Panel Grants Company Listing Request
Nasdaq Hearings Panel Grants Company Listing Request (BXRX)
0 min read
7/3/2023
‌
Baudax Bio Announces Acquisition of TeraImmune, Inc.
Baudax Bio Announces Acquisition of TeraImmune, Inc. (BXRX)
0 min read
6/8/2023
‌
More Positive Top-Line Results From Phase II BX1000 Trial
More Positive Top-Line Results From Phase II BX1000 Trial (BXRX)
0 min read

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
Log In
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.
Log In